Compare USNA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USNA | PHAR |
|---|---|---|
| Founded | 1992 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.7M | 925.2M |
| IPO Year | 1996 | 2020 |
| Metric | USNA | PHAR |
|---|---|---|
| Price | $17.91 | $12.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 109.4K | 14.3K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $1,060,902,000.00 | N/A |
| Revenue This Year | $3.90 | $10.04 |
| Revenue Next Year | $6.21 | $2.51 |
| P/E Ratio | ★ $42.59 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.60 | $9.54 |
| 52 Week High | $38.32 | $21.34 |
| Indicator | USNA | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 32.79 |
| Support Level | $16.77 | $11.84 |
| Resistance Level | $18.11 | $13.61 |
| Average True Range (ATR) | 0.72 | 0.40 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 29.16 | 10.88 |
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.